Progressive pulmonary fibrosis during a pandemic: assessment of risk factors and modern approaches to treatment

Elena N. Popova , Andrei B. Ponomarev

For citation:

Abstract

Complex of medicine that increases the body's resistance to the damaging effects of viruses during a pandemic in the long term will be an important tool not only to reduce the overall incidence of diseases, but also to improve the prognosis of those who have been ill due to the reduction of residual fibrotic changes in the lungs.

Key words: COVID-19, pulmonary fibrosis, antiviral agents.

References

1. Vremennye metodicheskie rekomendatsii "Profilaktika, diagnostika i lechenie novoi koronavirusnoi infektsii (COVID-19)". Versiia 9 (utv. Minzdravom Rossii 26 oktiabria 2020 g.) (in Russian).

2. Simonnet A, Chetboun M, Poissy J et al. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity 2020; 28 (7): 1195–9. DOI: 10.1002/oby.22831

3. Leung JM, Niikura M, Tony Yang Ch W, Sin DD. COVID-19 and COPD. Eur Respir J 2020; 56 (2): 2002108. DOI: 10.1183/13993003. 02108-2020

4. An Zyl-Smit RN, Richards G, Leone FT. Tobacco smoking and COVID-19 infection. Lancet Respir Med 2020; 8 (7): 664–5. DOI: 10.1016/S2213-2600(20)30239-3. PMID: 32464099; PMCID: PMC7247798.

5. Lippi G, Sanchis-Gomar F, Henry BM. Active smoking and COVID-19: a double-edged sword. Eur J Intern Med 2020; 77: 123–4. DOI: 10.1016/j.ejim.2020.04.060. PMID: 32439289; PMCID: PMC7252038.

6. Shi Y, Wang G, Cai XP, et al. An overview of COVID-19. J Zhejiang Univ Sci B 2020; 21 (5): 343–60. DOI: 10.1631/jzus.B2000083. PMID: 32425000; PMCID: PMC7205601.

7. Feng Y, Ling Y, Bai T et al. COVID-19 with different severity: a multi-center study of clinical features. Am J Respir Crit Care Med 2020; 201: 1380–8. DOI: 10.1164/rccm.202002-0445OC

8. Cai Q, Chen F, Wang T et al. Obesity and COVID-19 severity in a designated hospital in Shenzhen, China. Diabetes Care 2020; 43: 1392–8.

9. Leung JM, Yang CX, Tam A et al. ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19. Eur Respir J 2020; 55 (5): 2000688. DOI: 10.1183/ 13993003.00688-2020

10. Zhang H, Rostami MR, Leopold PL et al. Expression of the SARS-CoV-2 ACE2 receptor in the human airway epithelium. Am J Respir Crit Care Med 2020; 202: 219–29.

11. Ahmed H, Sayed A, Munir M et al. A Clinical Review of COVID-19; Pathogenesis, Diagnosis, and Management. Curr Pharm Des 2020.

E-pub Ahead of Print. DOI: 10.2174/1381612826666201222162509

12. Ojo AS, Balogun SA, Williams OT, Ojo OS. Pulmonary Fibrosis in COVID-19 Survivors: Predictive Factors and Risk Reduction Strategies. Pulm Med 2020: 6175964. E-pub Ahead of Print. DOI: 10.1155/2020/6175964. PMID: 32850151; PMCID: PMC7439160.

13. Lagi F, Piccica M, Graziani L et al. Early experience of an infectious and tropical diseases unit during the coronavirus disease (COVID-19) pandemic, Florence, Italy, February to March 2020. Euro Surveill 2020; 25: 2000556. DOI: 10.2807/1560-7917.ES.2020.25.17.2000556

14. Tyurina YY, Mikulska-Ruminska K et al. Pseudomonas aeruginosa utilizes host polyunsaturated phosphatidylethanolamines to trigger theft-ferroptosis in bronchial epithelium. J Clin Invest 2018; 128 (10): 4639–53. DOI: 10.1172/JCI99490

15. Kolb M, Vašáková M. The natural history of progressive fibrosing interstitial lung diseases. Respir Res 2019; 20 (1): 57. DOI: 10.1186/s12931-019-1022-1

16. Raghu G, Remy-Jardin M, Myers JL et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med 2018; 198: e44–e68. DOI: 10.1164/rccm.201807-1255ST

17. Sheng G, Chen P, Wei Y et al. Viral Infection Increases the Risk of Idiopathic Pulmonary Fibrosis: A Meta-Analysis. Chest 2020; 157 (5): 1175–87. DOI: 10.1016/j.chest.2019.10.032

18. Anand Devaraj. Imaging: how to recognise idiopathic pulmonary fibrosis. European Respiratory Review 2014; 23: 215–9; DOI: 10.1183/09059180.00001514

19. Rai DK, Sharma P, Kumar R. Post Covid-19 pulmonary fibrosis- Is it reversible? Indian J Tuberc 2020; 10. E-pub Ahead of Print. DOI: 10.1016/j.ijtb.2020.11.003

20. Gromova O.A., Torshin I.Yu. Combined therapy for treatment of acute respiratory viral infections: analysis of combined complex AnviMax. Medical alphabet. 2020; 21: 33–48. DOI: 10.33667/2078-5631-2020-21-33-48 (in Russian).

21. Kuzin V.B., Lovtsova L.V., Barsuk A.L. Issledovanie klinicheskoi effektivnosti i perenosimosti preparata Antigrippin-Maksimum pri lechenii ORVI (grippa). Spravochnik poliklinicheskogo vracha. 2010; 1: 3–7 (in Russian).

22. Hemila H, Chalker E. Vitamin C for preventing and treating the common cold. Cochrane Database SystRev 2013; 1: CD 000980.

23. Bai L, Li A, Gong C et al. Protective effect of rutin against bleomycin induced lung fibrosis: Involvement of TGF-beta1/alpha-SMA/Col I and III pathway. Biofactors 2020. DOI: 10,1002/biof.1629. PubMed ID: 32233122.

24. Ortolani O, Conti A, De Gaudio AR et al. Protective effects of N-acetylcysteine and rutin on the lipid peroxidation of the lung epithelium during the adult respiratory distress syndrome. Shock 2000; 13 (1): 14–8. DOI: 10.1097/00024382-200013010-00003. PMID: 10638663.

25. Ragheb SR et al. Impact of Rutin and Vitamin C combination on oxidative stress and glycemic control in patients with type 2 diabetes. Clinical Nutrition ESPEN 2020; 35: 128–35. DOI: 10.1016/j.clnesp.2019.10.015

For citation:Popova E.N., Ponomarev A.B. Progressive pulmonary fibrosis during a pandemic: assessment of risk factors and modern approaches to treatment. Clinical review for general practice. 2021; 1: 6–11. DOI: 10.47407/kr2021.2.1.00026

All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

Clinical review for general practice